Stephen Brady has been appointed president and chief operating officer of Tempest Therapeutics. Brady was most recently executive vice president of strategy and finance at Immune Design, which was acquired by Merck (NYSE: [[ticker:MRK]]) earlier this year. South San Francisco-based Tempest, a spinout of venture capital firm Versant Ventures, raised $70 million in Series B financing last year. The company’s lead drug, TPST-1120, is in early-stage testing in patients with solid tumors.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
